{"id":141,"date":"2023-11-21T10:00:00","date_gmt":"2023-11-21T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=141"},"modified":"2025-09-02T06:48:36","modified_gmt":"2025-09-02T06:48:36","slug":"china-bd-2023-haisco-and-chiesi-enters-a-license-475-million-usd-on-dpp1-inhibitor-hsk31858","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2023\/141.html","title":{"rendered":"[China BD 2023] Haisco and Chiesi enters a 475 million USD license on DPP1 inhibitor HSK31858"},"content":{"rendered":"\n<h1 class=\"wp-block-heading\"><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Announced Date: 2023-11-20 (November 20, 2023)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Name: HSK31858<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensor: Haisco Pharmaceutical Group (China)  and <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensee (Buyer): Chiesi Farmaceutici S.p.A\uff08Italy\uff09<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Modality: Small \u00a0Molecule, Oral<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Target: DPP1 (dipeptidyl peptidase 1 inhibitor)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Potential Indication: respiratory diseases<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Current Stage: Phase II, in China<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Scope of Authority:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Haisco has granted Chiesi an exclusive license to develop, manufacture, and commercialise outside greater China (including Hong Kong SAR, Macau SAR and Taiwan District) HSK31858.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Payment Detail:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Upfront payment of\u00a0 $13 million;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Milestone payments up to \u00a0$462 million;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Total up to $475 million.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Additional royalties based on net sales in the licensed territories.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Link:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.chiesi.com\/en\/agreement-haisco-pharmaceutical-reversible-dipeptidyl-peptidase-1-inhibitor-bronchiectasis\/\">Haisco Pharmaceutical | Chiesi Farmaceutici S.p.A.<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2023-11-20 (November 20, 2023) Asset Name: HSK31858 Licensor: Haisco Pharmaceutical Group (China) and Licensee &hellip; <a title=\"[China BD 2023] Haisco and Chiesi enters a 475 million USD license on DPP1 inhibitor HSK31858\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2023\/141.html\"><span class=\"screen-reader-text\">[China BD 2023] Haisco and Chiesi enters a 475 million USD license on DPP1 inhibitor HSK31858<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-141","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/141","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=141"}],"version-history":[{"count":2,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/141\/revisions"}],"predecessor-version":[{"id":143,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/141\/revisions\/143"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=141"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=141"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=141"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}